Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry

被引:29
作者
Al-Dirbashi, OY
Rashed, MS
Ten Brink, HJ
Jakobs, C
Filimban, N
Al-Ahaidib, LY
Jacob, M
Al-Sayed, MM
Al-Hassnan, Z
Faqeih, E
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh 11211, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Med Genet, Riyadh 11211, Saudi Arabia
[3] VU Med Ctr, Metab Lab, NL-1007 MB Amsterdam, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2006年 / 831卷 / 1-2期
关键词
hepatorenal tyrosinemia; tyrosine; succinylacetone; dansylhydrazine; tandem mass spectrometry; newborn screening;
D O I
10.1016/j.jchromb.2005.12.010
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Succinylacetone (SA) is a specific marker for the inherited metabolic disease, hepatorenal tyrosinemia. We developed a stable-isotope dilution liquid chromatography tandem mass spectrometry for the determination of SA in dried blood spots (DBS) and liquid urine using a C-13(4)-SA as internal standard. SA was extracted, converted to the butyl ester and derivatized with dansylhydrazine (Dns-H). Calibration curves in DBS and urine calibrators were linear up to 100 and 30 mu M, respectively. At a signal-to-noise ratio of 3, the limits of detection in DBS and urine were 0.2 and 0.005 mu M, respectively. Total run time was 5 min. Intra- and inter-assay precision expressed as coefficient of variation were better than 9.1% with more than 96% recovery. The method was applied retrospectively and prospectively for the diagnosis of hepatorenal tyrosinemia and for follow-up of patients under treatment. (c) 2005 Published by Elsevier B.V.
引用
收藏
页码:274 / 280
页数:7
相关论文
共 24 条
[1]   Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots [J].
Allard, P ;
Grenier, A ;
Korson, MS ;
Zytkovicz, TH .
CLINICAL BIOCHEMISTRY, 2004, 37 (11) :1010-1015
[2]   DEFICIENCY OF FUMARYLACETOACETASE IN A PATIENT WITH HEREDITARY TYROSINEMIA [J].
BERGER, R ;
SMIT, GPA ;
STOKERDEVRIES, SA ;
DURAN, M ;
KETTING, D ;
WADMAN, SK .
CLINICA CHIMICA ACTA, 1981, 114 (01) :37-44
[3]   Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns [J].
Chace, DH ;
Kalas, TA ;
Naylor, EW .
CLINICAL CHEMISTRY, 2003, 49 (11) :1797-1817
[4]   DETECTION OF SUCCINYLACETONE AND THE USE OF ITS MEASUREMENT IN MASS-SCREENING FOR HEREDITARY TYROSINEMIA [J].
GRENIER, A ;
LESCAULT, A ;
LABERGE, C ;
GAGNE, R ;
MAMER, O .
CLINICA CHIMICA ACTA, 1982, 123 (1-2) :93-99
[5]  
Holme Elisabeth, 1995, Current Opinion in Pediatrics, V7, P726
[6]   STABLE ISOTOPE-DILUTION ANALYSIS OF SUCCINYLACETONE USING ELECTRON-CAPTURE NEGATIVE-ION MASS FRAGMENTOGRAPHY - AN ACCURATE APPROACH TO THE PRENATAL AND NEONATAL DIAGNOSIS OF HEREDITARY TYROSINEMIA TYPE-I [J].
JAKOBS, C ;
DORLAND, L ;
WIKKERINK, B ;
KOK, RM ;
DEJONG, APJM ;
WADMAN, SK .
CLINICA CHIMICA ACTA, 1988, 171 (2-3) :223-231
[7]   DEFICIENT FUMARYLACETOACETATE FUMARYLHYDROLASE ACTIVITY IN LYMPHOCYTES AND FIBROBLASTS FROM PATIENTS WITH HEREDITARY TYROSINEMIA [J].
KVITTINGEN, EA ;
HALVORSEN, S ;
JELLUM, E .
PEDIATRIC RESEARCH, 1983, 17 (07) :541-544
[8]   ASSAY OF FUMARYLACETOACETATE FUMARYLHYDROLASE IN HUMAN-LIVER - DEFICIENT ACTIVITY IN A CASE OF HEREDITARY TYROSINEMIA [J].
KVITTINGEN, EA ;
JELLUM, E ;
STOKKE, O .
CLINICA CHIMICA ACTA, 1981, 115 (03) :311-319
[9]   TRYOSINAEMIA TYPE-I - AN UPDATE [J].
KVITTINGEN, EA .
JOURNAL OF INHERITED METABOLIC DISEASE, 1991, 14 (04) :554-562
[10]   TYROSINEMIA - TREATMENT AND OUTCOME [J].
KVITTINGEN, EA .
JOURNAL OF INHERITED METABOLIC DISEASE, 1995, 18 (04) :375-379